Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)
Bullboard Posts
User Avatar Image
(47)
•••
Post by TriumphSpitSixon Jan 30, 2020 6:48pm
378 Views
Post# 30622455

Thoughts on averaging up?

Thoughts on averaging up?I've been sitting on what is now just over 100k shares at an average of 10 cents USD (ATBPF). I had over 300k bought at lows in mid-2017 but have slowly sold 2/3 of my original position when it would pop to the mid-.40s. I have bought two distressed rental properties with Antibe profits (long rehabs ongoing.)

I've always been a buy and hold long and have averaged down ALOT on the Venture but have never averaged UP. Seems with all the promise Antibe holds, if ever there was a candidate for doing so, Antibe would be it. So, I'm considering pulling the trigger for like another $30k USD injection when/if it pulls back after today's pop.

Thoughts on averaging up in general or specifically regarding ATE?

BTW, it feels great to even be discussing this topic. I was in some of the wrong picks in 2019 (blockchain/tech) and have been faithfully holding and waiting on others (Theralase, Peak Positioning, Enerdynamic Hybrid Tech) with similar "blue sky" potential as Antibe.

...patience required...

Many thanks!
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities